Please Wait.....
Report
Radioligand Therapeutics in Cancer Treatment: Global Markets
Market Research Report I 2026-02-10 I 106 Pages I BCC Research
Description
Report Scope
This report provides an in-depth analysis of the global market for radioligand therapeutics (RLT) in cancer treatment. It presents detailed market data for 2024 (base year), estimates for 2025 and forecasts with compound annual growth rates (CAGR) through 2030. The study evaluates current market dynamics, emerging trends and future growth potential driven by the adoption of prostate-specific membrane antigen (PSMA)- and somatostatin receptor (SSTR)-targeted therapies.
The report assesses the competitive environment, including product-level analysis of approved radioligand therapies such as 177Lu-vipivotide tetraxetan (Pluvicto) and 177Lu-dotatate (Lutathera), as well as pipeline assets targeting PSMA, SSTR, gastrin?releasing peptide receptor (GRPR) and other tumor-specific receptors. It also examines regulatory pathways and reimbursement frameworks.
Market segmentation encompasses product type, indication type, and end user, with additional assessments of drivers, restraints, opportunities, technological advances, and strategic activities such as collaborations, acquisitions, clinical trial investments, and expansion of isotope production capacity.
Segmental-level market data (by product type, indication type and end user) is limited to the North America region. This limitation highlights that the market for radioligand therapeutics in cancer treatment is centered in the U.S., where a single company's products (Pluvicto and Lutathera from Novartis AG) account for the majority of global sales and where reliable, detailed data are accessible. In other regions, RLT is still in an early stage, with limited commercial adoption and insufficient transparent data to enable detailed segment-level analysis.
Report Includes
- 15 data tables and 57 additional tables
- Overview and an analysis of the global markets for radioligand therapeutics (RLT) in cancer treatment
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects for the global market, along with a corresponding market share analysis based on product type, disease indication, end user and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of macroeconomic variables
- Highlights of promising new advancements in precision oncology, the emergence of innovative and effective theranostic agents, applications and potential
- Insights derived from Porter's Five Forces model, as well as global supply chain analyses
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Novartis AG, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Ltd., RayzeBio Inc., and Lilly USA LLC.
Executive Summary
Summary:
The global market for radioligand therapeutics in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.1% from 2025 through 2030.
Radioligand therapy (RLT) utilizes targeted ligands to deliver therapeutic radionuclides to cancer cells, and is now clinically and regulatorily validated for the treatment of advanced prostate cancer expressing prostate-specific membrane antigen (PSMA-positive) and somatostatin receptor (SSTR)-expressing neuroendocrine tumors (NETs). Although the science dates back decades, commercial momentum has accelerated in recent years, with Novartis AG's Pluvicto (Lu-177 PSMA) and Lutathera (Lu-177 SSTR) now anchoring today's approved market. Radioligand therapy can produce durable benefits in selected patients, but it requires specialized infrastructure and careful management of treatment-related effects and radiation safety.
The field is rapidly evolving. Access to prostate-specific membrane antigen positron emission tomography (PSMA PET) and somatostatin receptor positron emission tomography (SSTR PET), the shift to earlier-line settings and combination regimens with standard care are expanding the eligible patient populations. At the same time, the supply of therapeutic isotopes and trained nuclear medicine personnel remains a significant constraint, especially outside leading centers. RLT in cancer treatment is expected to grow across North America, Europe and emerging markets through 2030, with the approved Lutetium-177 (Lu-177) products supporting near-term revenues and alpha-emitter and novel platform programs offering mid-term growth potential.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Current Market Scenario
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
Macroeconomic Factors Analysis
Geographical Factor
Healthcare Spend
Cancer Burden and Demographics
Reimbursement and Funding Climate
Impact of U.S. Tariffs on Radioligand Therapeutics in Cancer Treatment Supply Chains
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Cancer Incidence and Population Aging
Increasing Approvals and Label Expansions of Radioligand Therapeutics Products
Centers for Medicare and Medicaid Services (CMS) Separate Payment for Therapeutic Radiopharmaceuticals
Market Restraints/Challenges
Therapeutic Isotope Supply Constraints
Nuclear Medicine and Radiopharmacy Workforce Shortage
Growing Competition from Alternative Modalities such as Antibody-Drug Conjugates (ADCs)
Market Opportunities
Development of Alpha-Emitter Therapies and Novel Targets
Earlier-Line Use and Combination Regimens with Standard of Care
Increasing R&D Investments and Strategic Alliances
Chapter 4 Regulatory Landscape
Overview
Regulatory Frameworks by Country/Region
U.S.
Canada
Europe
Emerging Markets
Chapter 5 Emerging Technologies and Developments
Key Takeaways
Targeted Alpha Therapies (TATs)
Next-Generation Isotopes and Smarter Ligands
Personalized, Dosimetry-Guided RLT (AI-Assisted)
Chapter 6 Pipeline and Clinical Analysis
Key Takeaways
Pipeline Analysis
Clinical Trials Analysis
Key Takeaways
Clinical Trial Studies on Radioligand Therapeutics in Cancer Treatment
Chapter 7 Patent Analysis
Key Takeaways
Patent Analysis
Recent Patent Grants
Chapter 8 Market Segmentation Analysis
Segmentation Breakdown
Global Market for Radioligand Therapeutics in Cancer Treatment, by Product Type
Key Takeaways
Lutetium-177 Dotatate
Others (Pipeline)
Global Market for Radioligand Therapeutics in Cancer Treatment, by Indication
Key Takeaways
Prostate Cancer
Neuroendocrine Tumors
Others (Pipeline)
Global Market for Radioligand Therapeutics in Cancer Treatment, by End User
Key Takeaways
Academic/Comprehensive Cancer Centers
Hospital-Based Nuclear Medicine
Specialized Private Nuclear Medicine Clinics
Geographic Breakdown
Global Market for Radioligand Therapeutics in Cancer Treatment, by Region
Key Takeaways
North America
Europe
Emerging Markets
Chapter 9 Competitive Intelligence
Competitive Landscape
Key Takeaways
Novartis AG RLT Sales, 2024
Other Competitors in the Pipeline
Chapter 10 Sustainability in the Global Market for Radioligand Therapeutics in Cancer Treatment: An ESG Perspective
Introduction to ESG
Sustainability in the Global Market for Radioligand Therapeutics in Cancer Treatment
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion
Chapter 11 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ABDERA THERAPEUTICS
ARICEUM THERAPEUTICS
CLARITY PHARMACEUTICALS
CONVERGENT THERAPEUTICS INC.
CURIUM
FUSION PHARMA
ITM ISOTOPE TECHNOLOGIES MUNICH SE
LILLY USA LLC.
NOVARTIS AG
ORANO MED
PERSPECTIVE THERAPEUTICS
PRECIRIX
RADIOPHARM THERANOSTICS LTD.
RAYZEBIO INC.
TELIX PHARMACEUTICALS LTD.
Few Emerging Companies in the Global Market for Radioligand Therapeutics in Cancer Treatment
List of Tables
Summary Table : Global Market for Radioligand Therapeutics in Cancer Treatment, by Region, Through 2030
Table 1 : Clinical-Commercial Heatmap, by Target and Indication, 2025-2030 Outlook
Table 2 : Healthcare Spending Snapshot and Implications for Radioligand Therapeutics Rollout (Developed versus Emerging Markets)
Table 3 : Reimbursement and Funding Climate, 2024 and 2025
Table 4 : Recent U.S. Regulatory Actions Affecting Radioligand Therapeutics
Table 5 : Selected Clinical Trials Studies on Radioligand Therapeutics in Cancer Treatment
Table 6 : Recent Patents in Radioligand Therapeutics in Cancer Treatment, 2024 and 2025
Table 7 : Global Market for Radioligand Therapeutics in Cancer Treatment, by Product Type, 2022-2024
Table 8 : Global Market for Radioligand Therapeutics in Cancer Treatment, by Indication, 2022-2024
Table 9 : Global Market for Radioligand Therapeutics in Cancer Treatment, by End User, Through 2030
Table 10 : Global Market for Radioligand Therapeutics in Cancer Treatment, by Region, Through 2030
Table 11 : North American Market for Radioligand Therapeutics in Cancer Treatment, by Product Type, Through 2030
Table 12 : North American Market for Radioligand Therapeutics in Cancer Treatment, by Indication, Through 2030
Table 13 : North American Market for Radioligand Therapeutics in Cancer Treatment, by End User, Through 2030
Table 14 : North American Market for Radioligand Therapeutics in Cancer Treatment, by Country, Through 2030
Table 15 : European Market for Radioligand Therapeutics in Cancer Treatment, Through 2030
Table 16 : Emerging Regions' Market for Radioligand Therapeutics in Cancer Treatment, Through 2030
Table 17 : Strategic Initiatives in the Global Market for Radioligand Therapeutics in Cancer Treatment, 2025
Table 18 : Key Focus Areas in ESG Metrics
Table 19 : ESG Rankings for Leading Companies in the Global Market for Radioligand Therapeutics in Cancer Treatment, 2025*
Table 20 : Abbreviations Used in this Report
Table 21 : Report Sources
Table 22 : Abdera Therapeutics: Company Snapshot
Table 23 : Abdera Therapeutics: Product Pipeline
Table 24 : Abdera Therapeutics: News/Key Developments, 2023 and 2024
Table 25 : Ariceum Therapeutics: Company Snapshot
Table 26 : Ariceum Therapeutics: Product Pipeline
Table 27 : Ariceum Therapeutics: News/Key Developments, 2022-2025
Table 28 : Clarity Pharmaceuticals: Company Snapshot
Table 29 : Clarity Pharmaceuticals: Product Pipeline
Table 30 : Clarity Pharmaceuticals: News/Key Developments, 2024 and 2025
Table 31 : Convergent Therapeutics Inc.: Company Snapshot
Table 32 : Convergent Therapeutics Inc.: Product Pipeline
Table 33 : Convergent Therapeutics Inc.: News/Key Developments, 2022-2025
Table 34 : Curium: Company Snapshot
Table 35 : Curium: Product Pipeline
Table 36 : Curium: News/Key Developments, 2024
Table 37 : Fusion Pharma: Company Snapshot
Table 38 : Fusion Pharma: Product Pipeline
Table 39 : Fusion Pharma: News/Key Developments, 2024
Table 40 : ITM Isotope Technologies Munich SE: Company Snapshot
Table 41 : ITM Isotope Technologies Munich SE: Product Pipeline
Table 42 : ITM Isotope Technologies Munich SE: News/Key Developments, 2024 and 2025
Table 43 : Lilly USA LLC.: Company Snapshot
Table 44 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 45 : Lilly USA LLC.: Product Pipeline
Table 46 : Lilly USA LLC.: News/Key Developments, 2023-2025
Table 47 : Novartis AG: Company Snapshot
Table 48 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 49 : Novartis AG: Product Portfolio
Table 50 : Novartis AG: News/Key Developments, 2023-2024
Table 51 : Orano Med: Company Snapshot
Table 52 : Orano Med: Product Pipeline
Table 53 : Orano Med: News/Key Developments, 2023-2025
Table 54 : Perspective Therapeutics: Company Snapshot
Table 55 : Perspective Therapeutics: Financial Performance, FY 2023 and 2024
Table 56 : Perspective Therapeutics: Product Pipeline
Table 57 : Perspective Therapeutics: News/Key Developments, 2023 and 2024
Table 58 : Precirix: Company Snapshot
Table 59 : Precirix: Product Pipeline
Table 60 : Precirix: News/Key Developments, 2025
Table 61 : Radiopharm Theranostics Ltd.: Company Snapshot
Table 62 : Radiopharm Theranostics Ltd.: Product Pipeline
Table 63 : Radiopharm Theranostics Ltd.: News/Key Developments, 2024 and 2025
Table 64 : RayzeBio Inc.: Company Snapshot
Table 65 : RayzeBio Inc.: Product Pipeline
Table 66 : RayzeBio Inc.: News/Key Developments, 2024
Table 67 : Telix Pharmaceuticals Ltd.: Company Snapshot
Table 68 : Telix Pharmaceuticals Ltd.: Financial Performance, FY 2023 and 2024
Table 69 : Telix Pharmaceuticals Ltd.: Product Pipeline
Table 70 : Telix Pharmaceuticals Ltd.: News/Key Developments, 2024 and 2025
Table 71 : Few Emerging Companies in the Global Market for Radioligand Therapeutics in Cancer Treatment
List of Figures
Summary Figure : Global Market Shares for Radioligand Therapeutics in Cancer Treatment, by Region, 2024
Figure 1 : Global RLT Relevant Cancer Burden Versus Ageing Trend, 2022
Figure 2 : Porter's Five Forces Analysis of the Global Market for Radioligand Therapeutics in Cancer Treatment
Figure 3 : Market Dynamics of Radioligand Therapeutics in Cancer Treatment
Figure 4 : Global Market Shares for Radioligand Therapeutics in Cancer Treatment, by Product Type, 2024
Figure 5 : Global Market Shares for Radioligand Therapeutics in Cancer Treatment, by Indication, 2024
Figure 6 : Global Market Shares for Radioligand Therapeutics in Cancer Treatment, by End User, 2024
Figure 7 : Global Market Shares for Radioligand Therapeutics in Cancer Treatment, by Region, 2024
Figure 8 : North American Market Shares for Radioligand Therapeutics in Cancer Treatment, by Product Type, 2024
Figure 9 : North American Market Shares for Radioligand Therapeutics in Cancer Treatment, by Indication, 2024
Figure 10 : North American Market Shares for Radioligand Therapeutics in Cancer Treatment, by End User, 2024
Figure 11 : North American Market Shares for Radioligand Therapeutics in Cancer Treatment, by Country, 2024
Figure 12 : Advantages of ESG for Companies
Figure 13 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
Figure 14 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 15 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 16 : Telix Pharmaceuticals Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 17 : Telix Pharmaceuticals Ltd.: Revenue Share, by Country/Region, FY 2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security